| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 58 | 2023 | 1403 | 6.670 |
Why?
|
| Hodgkin Disease | 32 | 2024 | 1378 | 5.310 |
Why?
|
| Mediastinal Neoplasms | 16 | 2023 | 402 | 2.610 |
Why?
|
| Lymphoma, B-Cell | 26 | 2019 | 935 | 2.430 |
Why?
|
| Reed-Sternberg Cells | 10 | 2019 | 72 | 2.130 |
Why?
|
| Chromosomes, Human, Pair 9 | 9 | 2019 | 534 | 1.860 |
Why?
|
| Galectin 1 | 9 | 2017 | 128 | 1.770 |
Why?
|
| Lymphoma, Non-Hodgkin | 21 | 2023 | 1375 | 1.520 |
Why?
|
| Neoplasm Proteins | 15 | 2019 | 3610 | 1.390 |
Why?
|
| Neprilysin | 21 | 2001 | 472 | 1.370 |
Why?
|
| Lymphoma | 13 | 2023 | 1898 | 1.220 |
Why?
|
| Receptors, Antigen, B-Cell | 9 | 2023 | 545 | 1.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 24 | 2019 | 8515 | 1.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 8 | 2016 | 2873 | 0.940 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2019 | 2418 | 0.860 |
Why?
|
| Chromosome Aberrations | 8 | 2016 | 1764 | 0.860 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 3844 | 0.780 |
Why?
|
| Janus Kinase 2 | 4 | 2014 | 542 | 0.770 |
Why?
|
| Transcription Factor AP-1 | 4 | 2012 | 321 | 0.760 |
Why?
|
| Tumor Escape | 3 | 2021 | 370 | 0.740 |
Why?
|
| Doxorubicin | 19 | 2024 | 2209 | 0.710 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2012 | 533 | 0.700 |
Why?
|
| Testicular Neoplasms | 2 | 2017 | 801 | 0.690 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2023 | 581 | 0.660 |
Why?
|
| Cytophotometry | 1 | 2018 | 8 | 0.640 |
Why?
|
| Vincristine | 17 | 2016 | 1039 | 0.620 |
Why?
|
| Antineoplastic Agents | 16 | 2018 | 13630 | 0.600 |
Why?
|
| Gene Dosage | 5 | 2016 | 1218 | 0.600 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2017 | 916 | 0.600 |
Why?
|
| Immune Evasion | 2 | 2019 | 362 | 0.590 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2012 | 1889 | 0.550 |
Why?
|
| Metalloendopeptidases | 7 | 2005 | 393 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 25 | 2024 | 11712 | 0.540 |
Why?
|
| Translocation, Genetic | 8 | 2015 | 1388 | 0.530 |
Why?
|
| Signal Transduction | 18 | 2023 | 23376 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-rel | 5 | 2007 | 71 | 0.510 |
Why?
|
| Antibodies, Monoclonal | 10 | 2017 | 9185 | 0.490 |
Why?
|
| Antigens, Differentiation | 8 | 1992 | 911 | 0.470 |
Why?
|
| Apoptosis | 14 | 2018 | 9501 | 0.470 |
Why?
|
| Drug Synergism | 1 | 2018 | 1754 | 0.470 |
Why?
|
| DNA Copy Number Variations | 4 | 2019 | 2013 | 0.470 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2018 | 1446 | 0.470 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 895 | 0.460 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2018 | 1407 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2013 | 19 | 0.450 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2023 | 5649 | 0.440 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 2 | 2009 | 24 | 0.430 |
Why?
|
| Immunoconjugates | 6 | 2023 | 949 | 0.430 |
Why?
|
| Cell Transformation, Viral | 2 | 2012 | 526 | 0.420 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2012 | 50 | 0.420 |
Why?
|
| Cyclophosphamide | 15 | 2014 | 2221 | 0.410 |
Why?
|
| Sulfonamides | 3 | 2018 | 1977 | 0.410 |
Why?
|
| Poly(ADP-ribose) Polymerases | 4 | 2012 | 428 | 0.410 |
Why?
|
| Trans-Activators | 5 | 2019 | 2860 | 0.410 |
Why?
|
| Gene Expression Profiling | 18 | 2016 | 9411 | 0.410 |
Why?
|
| Quinazolines | 1 | 2018 | 1363 | 0.400 |
Why?
|
| DNA-Binding Proteins | 10 | 2013 | 9585 | 0.400 |
Why?
|
| Protein Tyrosine Phosphatases | 3 | 2009 | 459 | 0.390 |
Why?
|
| Humans | 170 | 2024 | 760621 | 0.390 |
Why?
|
| Genes, p53 | 2 | 2016 | 713 | 0.380 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 2203 | 0.370 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 2864 | 0.370 |
Why?
|
| Antigens, Neoplasm | 9 | 2006 | 1998 | 0.370 |
Why?
|
| Tumor Cells, Cultured | 14 | 2018 | 6131 | 0.370 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2016 | 223 | 0.350 |
Why?
|
| Oxazines | 2 | 2009 | 341 | 0.350 |
Why?
|
| B-Lymphocytes | 11 | 2010 | 4742 | 0.350 |
Why?
|
| Cell Line, Tumor | 18 | 2014 | 16939 | 0.340 |
Why?
|
| Vinblastine | 2 | 2024 | 487 | 0.330 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2002 | 237 | 0.330 |
Why?
|
| Genetic Heterogeneity | 5 | 2018 | 724 | 0.330 |
Why?
|
| Pyrimidines | 3 | 2018 | 3016 | 0.330 |
Why?
|
| Cell Cycle | 2 | 2012 | 2934 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2023 | 9276 | 0.320 |
Why?
|
| Antigens, CD | 5 | 2010 | 4000 | 0.320 |
Why?
|
| Mice, Inbred NOD | 4 | 2018 | 1837 | 0.320 |
Why?
|
| Burkitt Lymphoma | 3 | 2014 | 333 | 0.310 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2023 | 4550 | 0.310 |
Why?
|
| Benzoquinones | 1 | 2008 | 198 | 0.300 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2012 | 607 | 0.300 |
Why?
|
| beta 2-Microglobulin | 3 | 2018 | 328 | 0.300 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4353 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 7 | 2013 | 191 | 0.290 |
Why?
|
| Neoplasm Staging | 15 | 2024 | 11152 | 0.290 |
Why?
|
| Promoter Regions, Genetic | 6 | 2013 | 5785 | 0.290 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2010 | 301 | 0.290 |
Why?
|
| Mutation | 10 | 2019 | 29932 | 0.290 |
Why?
|
| Cell Proliferation | 10 | 2018 | 10446 | 0.290 |
Why?
|
| Genomics | 2 | 2019 | 5794 | 0.280 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 315 | 0.280 |
Why?
|
| Mice, SCID | 3 | 2018 | 2627 | 0.280 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2006 | 46 | 0.270 |
Why?
|
| Molecular Sequence Data | 18 | 2015 | 17624 | 0.270 |
Why?
|
| Genetic Loci | 1 | 2015 | 2618 | 0.270 |
Why?
|
| NF-kappa B | 4 | 2013 | 2488 | 0.270 |
Why?
|
| Herpesvirus 4, Human | 2 | 2013 | 1075 | 0.270 |
Why?
|
| Prednisone | 8 | 2016 | 1565 | 0.260 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2018 | 3075 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2007 | 362 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2019 | 126 | 0.260 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 423 | 0.260 |
Why?
|
| Switzerland | 2 | 2023 | 323 | 0.260 |
Why?
|
| Transplantation, Autologous | 8 | 2023 | 2116 | 0.260 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2012 | 608 | 0.250 |
Why?
|
| I-kappa B Proteins | 1 | 2006 | 212 | 0.250 |
Why?
|
| Genes, Neoplasm | 2 | 2018 | 370 | 0.250 |
Why?
|
| Antigens, Surface | 4 | 1992 | 1608 | 0.250 |
Why?
|
| Protein Kinase C | 2 | 2007 | 1199 | 0.250 |
Why?
|
| Alternative Splicing | 4 | 1999 | 1091 | 0.240 |
Why?
|
| Lysine | 1 | 2009 | 1001 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 3584 | 0.240 |
Why?
|
| Paraffin Embedding | 2 | 2024 | 302 | 0.240 |
Why?
|
| Gene Expression | 9 | 2017 | 7588 | 0.240 |
Why?
|
| Lymphoma, T-Cell | 4 | 2016 | 305 | 0.230 |
Why?
|
| Genes | 4 | 2007 | 1845 | 0.230 |
Why?
|
| Transcription, Genetic | 9 | 2013 | 7593 | 0.230 |
Why?
|
| Immunohistochemistry | 15 | 2016 | 11071 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2009 | 5643 | 0.220 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2023 | 87 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2014 | 995 | 0.220 |
Why?
|
| Gene Rearrangement | 3 | 2018 | 1122 | 0.220 |
Why?
|
| Bleomycin | 7 | 2016 | 495 | 0.220 |
Why?
|
| Gene Deletion | 3 | 2012 | 2668 | 0.220 |
Why?
|
| Antigen Presentation | 3 | 2018 | 1254 | 0.210 |
Why?
|
| Ubiquitin | 2 | 2009 | 838 | 0.210 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 2802 | 0.200 |
Why?
|
| Histones | 2 | 2010 | 2583 | 0.200 |
Why?
|
| Lymphocyte Activation | 6 | 2020 | 5496 | 0.200 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 3446 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 2919 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2010 | 1596 | 0.200 |
Why?
|
| Nuclear Proteins | 3 | 2013 | 5791 | 0.200 |
Why?
|
| Ligases | 1 | 2003 | 332 | 0.190 |
Why?
|
| Transfection | 8 | 2003 | 5781 | 0.190 |
Why?
|
| Dacarbazine | 1 | 2024 | 560 | 0.190 |
Why?
|
| Blotting, Western | 7 | 2014 | 5039 | 0.190 |
Why?
|
| Congresses as Topic | 2 | 2023 | 805 | 0.190 |
Why?
|
| Salvage Therapy | 4 | 2020 | 1268 | 0.190 |
Why?
|
| TNF Receptor-Associated Factor 1 | 3 | 2007 | 50 | 0.190 |
Why?
|
| Etoposide | 3 | 2016 | 630 | 0.190 |
Why?
|
| Base Sequence | 13 | 2015 | 12446 | 0.190 |
Why?
|
| Exons | 4 | 2012 | 2388 | 0.190 |
Why?
|
| Prednisolone | 1 | 2002 | 327 | 0.180 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2016 | 2506 | 0.180 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 6828 | 0.180 |
Why?
|
| Treatment Outcome | 20 | 2024 | 65017 | 0.180 |
Why?
|
| Histiocytes | 1 | 2021 | 98 | 0.180 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 274 | 0.180 |
Why?
|
| Pyridines | 2 | 2009 | 2879 | 0.180 |
Why?
|
| Protein Structure, Tertiary | 4 | 2012 | 3800 | 0.180 |
Why?
|
| Viral Matrix Proteins | 2 | 2012 | 197 | 0.170 |
Why?
|
| Toll-Like Receptors | 1 | 2023 | 590 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2005 | 5251 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2016 | 1355 | 0.170 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2023 | 568 | 0.170 |
Why?
|
| DNA Damage | 1 | 2009 | 2442 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2009 | 3775 | 0.170 |
Why?
|
| Cell Line | 12 | 2012 | 15620 | 0.170 |
Why?
|
| Adult | 38 | 2024 | 219994 | 0.160 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2009 | 1974 | 0.160 |
Why?
|
| Prognosis | 21 | 2019 | 29658 | 0.160 |
Why?
|
| Flavonoids | 1 | 2002 | 445 | 0.160 |
Why?
|
| DNA, Complementary | 5 | 2005 | 1991 | 0.160 |
Why?
|
| Bombesin | 3 | 1994 | 35 | 0.160 |
Why?
|
| Indoles | 1 | 2007 | 1829 | 0.160 |
Why?
|
| Mice | 22 | 2023 | 81208 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 3 | 2014 | 2640 | 0.160 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2009 | 1628 | 0.150 |
Why?
|
| Ubiquitination | 3 | 2012 | 1008 | 0.150 |
Why?
|
| T-Lymphocytes | 6 | 2021 | 10181 | 0.150 |
Why?
|
| Stromal Cells | 3 | 2000 | 1326 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 4573 | 0.150 |
Why?
|
| Male | 45 | 2024 | 359744 | 0.150 |
Why?
|
| Matrix Metalloproteinase 11 | 5 | 2004 | 15 | 0.150 |
Why?
|
| Interferon-gamma | 1 | 2006 | 3157 | 0.150 |
Why?
|
| RNA, Small Interfering | 5 | 2016 | 3442 | 0.150 |
Why?
|
| Cloning, Molecular | 5 | 2005 | 4169 | 0.150 |
Why?
|
| Immunophenotyping | 4 | 2016 | 1871 | 0.150 |
Why?
|
| Tumor Burden | 2 | 2014 | 1895 | 0.140 |
Why?
|
| Presbyopia | 1 | 1997 | 10 | 0.140 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 3 | 2011 | 25 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 1996 | 1547 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2007 | 4490 | 0.140 |
Why?
|
| Animals | 30 | 2023 | 167963 | 0.140 |
Why?
|
| Amino Acid Sequence | 9 | 2005 | 13451 | 0.140 |
Why?
|
| Lung Neoplasms | 7 | 2005 | 13262 | 0.140 |
Why?
|
| Interleukin-8 | 1 | 2000 | 698 | 0.140 |
Why?
|
| Middle Aged | 35 | 2024 | 220352 | 0.140 |
Why?
|
| Cell Division | 8 | 2007 | 4463 | 0.140 |
Why?
|
| STAT Transcription Factors | 2 | 2014 | 188 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2019 | 4122 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2014 | 748 | 0.140 |
Why?
|
| Female | 47 | 2024 | 391270 | 0.140 |
Why?
|
| Remission Induction | 7 | 2019 | 2392 | 0.130 |
Why?
|
| Mechlorethamine | 1 | 2016 | 129 | 0.130 |
Why?
|
| Subrenal Capsule Assay | 1 | 2016 | 27 | 0.130 |
Why?
|
| Gallium Radioisotopes | 1 | 1997 | 195 | 0.130 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2004 | 818 | 0.130 |
Why?
|
| Combined Modality Therapy | 6 | 2016 | 8552 | 0.130 |
Why?
|
| Carrier Proteins | 3 | 2012 | 4938 | 0.130 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2013 | 1356 | 0.130 |
Why?
|
| Recombinant Proteins | 5 | 2009 | 6538 | 0.130 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1998 | 590 | 0.130 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2010 | 678 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
| Pseudogenes | 1 | 2015 | 103 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2013 | 1135 | 0.120 |
Why?
|
| Lung | 5 | 2000 | 9994 | 0.120 |
Why?
|
| Enkephalin, Methionine | 3 | 1992 | 26 | 0.120 |
Why?
|
| Leucovorin | 6 | 2004 | 641 | 0.120 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 1995 | 128 | 0.120 |
Why?
|
| Gene Amplification | 3 | 2016 | 1085 | 0.120 |
Why?
|
| Aged | 26 | 2024 | 169152 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 728 | 0.120 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 2 | 1991 | 221 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2013 | 2448 | 0.120 |
Why?
|
| Chromatin Immunoprecipitation | 4 | 2011 | 858 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 693 | 0.120 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2014 | 85 | 0.120 |
Why?
|
| Cell Lineage | 3 | 2016 | 2533 | 0.120 |
Why?
|
| RNA Interference | 4 | 2016 | 2846 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 1996 | 535 | 0.110 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 1895 | 0.110 |
Why?
|
| Cohort Studies | 7 | 2019 | 41335 | 0.110 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1993 | 141 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 2221 | 0.110 |
Why?
|
| Hematopoiesis | 2 | 1993 | 2050 | 0.110 |
Why?
|
| Substance P | 2 | 1991 | 333 | 0.110 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 263 | 0.110 |
Why?
|
| Piperidines | 1 | 2002 | 1650 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 2 | 2013 | 1612 | 0.110 |
Why?
|
| Cell Line, Transformed | 2 | 2011 | 869 | 0.110 |
Why?
|
| Proto-Oncogenes | 2 | 1998 | 320 | 0.110 |
Why?
|
| Pyrrolidines | 2 | 2014 | 340 | 0.110 |
Why?
|
| HLA Antigens | 1 | 2018 | 1368 | 0.100 |
Why?
|
| Tretinoin | 1 | 1995 | 519 | 0.100 |
Why?
|
| Oxidative Phosphorylation | 3 | 2016 | 495 | 0.100 |
Why?
|
| Histone Chaperones | 1 | 2012 | 82 | 0.100 |
Why?
|
| Cytarabine | 2 | 2004 | 696 | 0.100 |
Why?
|
| Methotrexate | 7 | 2004 | 1719 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 3 | 2016 | 4713 | 0.100 |
Why?
|
| Genes, p16 | 1 | 2012 | 159 | 0.100 |
Why?
|
| Hematologic Diseases | 3 | 2009 | 496 | 0.100 |
Why?
|
| Dipeptides | 2 | 1993 | 409 | 0.100 |
Why?
|
| E2F Transcription Factors | 1 | 2012 | 269 | 0.100 |
Why?
|
| Bivalvia | 2 | 1991 | 53 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 1999 | 1173 | 0.100 |
Why?
|
| Proteins | 3 | 2003 | 6029 | 0.100 |
Why?
|
| Endopeptidases | 1 | 1995 | 772 | 0.100 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1995 | 788 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 2536 | 0.090 |
Why?
|
| Germinal Center | 2 | 2011 | 379 | 0.090 |
Why?
|
| Pre-B Cell Receptors | 1 | 2010 | 3 | 0.090 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2012 | 131 | 0.090 |
Why?
|
| Mesna | 2 | 2004 | 62 | 0.090 |
Why?
|
| YY1 Transcription Factor | 1 | 2011 | 59 | 0.090 |
Why?
|
| Hemocytes | 1 | 1990 | 44 | 0.090 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 58995 | 0.090 |
Why?
|
| Flow Cytometry | 4 | 2011 | 5870 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2007 | 629 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 631 | 0.090 |
Why?
|
| Cell Adhesion Molecules | 2 | 1998 | 1602 | 0.090 |
Why?
|
| F-Box Proteins | 1 | 2012 | 202 | 0.090 |
Why?
|
| RNA | 3 | 2015 | 2722 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 1755 | 0.090 |
Why?
|
| Restriction Mapping | 4 | 1998 | 852 | 0.080 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2011 | 241 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2017 | 3484 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 1991 | 416 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 276 | 0.080 |
Why?
|
| Sarcoma, Kaposi | 1 | 2012 | 376 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 15289 | 0.080 |
Why?
|
| Leukemia | 2 | 2016 | 1520 | 0.080 |
Why?
|
| Survival Analysis | 7 | 2017 | 10182 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 698 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 5 | 2014 | 6068 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2006 | 315 | 0.080 |
Why?
|
| Enzyme Activation | 4 | 2008 | 3602 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2010 | 377 | 0.080 |
Why?
|
| Cell Movement | 2 | 2000 | 5206 | 0.080 |
Why?
|
| Tissue Fixation | 2 | 2024 | 241 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 410 | 0.080 |
Why?
|
| Neoplasms | 5 | 2016 | 22072 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 2010 | 2825 | 0.080 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 2014 | 0.080 |
Why?
|
| Formaldehyde | 2 | 2024 | 358 | 0.080 |
Why?
|
| Young Adult | 10 | 2024 | 58741 | 0.080 |
Why?
|
| Hydroxyurea | 1 | 2009 | 282 | 0.080 |
Why?
|
| Drug Administration Schedule | 6 | 2017 | 4899 | 0.080 |
Why?
|
| Leukemia, Lymphoid | 1 | 1988 | 310 | 0.080 |
Why?
|
| Mast Cells | 1 | 1995 | 1390 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 3 | 2016 | 2803 | 0.070 |
Why?
|
| Protein Binding | 4 | 2012 | 9335 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 1996 | 2440 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2003 | 2753 | 0.070 |
Why?
|
| Cytokines | 3 | 2011 | 7343 | 0.070 |
Why?
|
| Coculture Techniques | 3 | 2004 | 1342 | 0.070 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2007 | 88 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2002 | 2557 | 0.070 |
Why?
|
| Transcription Factors | 5 | 2013 | 12103 | 0.070 |
Why?
|
| Mitochondria | 3 | 2016 | 3600 | 0.070 |
Why?
|
| Diagnosis, Differential | 6 | 2014 | 12965 | 0.070 |
Why?
|
| Stem Cell Transplantation | 3 | 2023 | 1599 | 0.070 |
Why?
|
| Nitrophenols | 1 | 2007 | 169 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2012 | 3607 | 0.070 |
Why?
|
| Spleen | 4 | 2011 | 2298 | 0.070 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2006 | 21 | 0.070 |
Why?
|
| Adolescent | 10 | 2024 | 87810 | 0.070 |
Why?
|
| Methylation | 1 | 2009 | 1082 | 0.070 |
Why?
|
| Acetylation | 1 | 2009 | 1062 | 0.070 |
Why?
|
| RNA, Messenger | 5 | 2007 | 12766 | 0.070 |
Why?
|
| DNA, Neoplasm | 2 | 1989 | 1745 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2010 | 646 | 0.070 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2008 | 167 | 0.070 |
Why?
|
| Morpholines | 1 | 2009 | 583 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1994 | 951 | 0.070 |
Why?
|
| Protein Isoforms | 2 | 2008 | 1697 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2000 | 3735 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2007 | 2907 | 0.070 |
Why?
|
| Nucleosomes | 1 | 2009 | 484 | 0.070 |
Why?
|
| Polysaccharides | 1 | 2012 | 1016 | 0.070 |
Why?
|
| Chemotaxis | 1 | 2009 | 598 | 0.060 |
Why?
|
| Recurrence | 4 | 2017 | 8482 | 0.060 |
Why?
|
| Aminopyridines | 1 | 2009 | 564 | 0.060 |
Why?
|
| Genes, ras | 1 | 1988 | 655 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2006 | 246 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3804 | 0.060 |
Why?
|
| Cell Membrane | 2 | 2004 | 3682 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2006 | 286 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 2717 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2006 | 532 | 0.060 |
Why?
|
| Dexamethasone | 6 | 1991 | 1927 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 280 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 2053 | 0.060 |
Why?
|
| Gene Expression Regulation | 4 | 2011 | 11903 | 0.060 |
Why?
|
| Glycopeptides | 3 | 1991 | 220 | 0.060 |
Why?
|
| Multiple Myeloma | 2 | 2016 | 5130 | 0.060 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2004 | 48 | 0.060 |
Why?
|
| Phosphorylation | 4 | 2006 | 8313 | 0.060 |
Why?
|
| Mediastinal Diseases | 1 | 2005 | 91 | 0.060 |
Why?
|
| Spectrometry, Mass, Secondary Ion | 1 | 2024 | 15 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5253 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 1993 | 1894 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2012 | 1055 | 0.060 |
Why?
|
| Cholesterol | 1 | 2013 | 2924 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 2 | 1995 | 3387 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2005 | 10827 | 0.060 |
Why?
|
| Hemoptysis | 1 | 2005 | 152 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 1765 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 2049 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 2003 | 0.060 |
Why?
|
| Ifosfamide | 1 | 2004 | 232 | 0.060 |
Why?
|
| Receptors, Bombesin | 2 | 1994 | 26 | 0.060 |
Why?
|
| Immunoblotting | 3 | 2012 | 1649 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 695 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 422 | 0.050 |
Why?
|
| DNA Repair | 1 | 2012 | 2039 | 0.050 |
Why?
|
| Follow-Up Studies | 8 | 2023 | 39261 | 0.050 |
Why?
|
| Clinical Trials as Topic | 4 | 2006 | 8056 | 0.050 |
Why?
|
| Binding Sites | 1 | 1992 | 6048 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2001 | 15840 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2009 | 3105 | 0.050 |
Why?
|
| Palatine Tonsil | 2 | 1999 | 193 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2006 | 2913 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 1652 | 0.050 |
Why?
|
| Diarrhea | 1 | 2009 | 1319 | 0.050 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 117 | 0.050 |
Why?
|
| Genes, MHC Class II | 1 | 1983 | 451 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 184 | 0.050 |
Why?
|
| Oligonucleotide Probes | 2 | 1993 | 418 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2012 | 2698 | 0.050 |
Why?
|
| Karyotyping | 3 | 1997 | 1171 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2006 | 814 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2007 | 992 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2003 | 814 | 0.050 |
Why?
|
| Enzyme Induction | 2 | 2004 | 452 | 0.050 |
Why?
|
| Piperazines | 3 | 2016 | 2525 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2012 | 4107 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 2895 | 0.050 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2003 | 458 | 0.050 |
Why?
|
| STAT1 Transcription Factor | 1 | 2003 | 333 | 0.050 |
Why?
|
| Time Factors | 7 | 2019 | 40165 | 0.050 |
Why?
|
| Th2 Cells | 1 | 2007 | 1047 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2003 | 435 | 0.050 |
Why?
|
| Nucleic Acid Conformation | 2 | 1996 | 899 | 0.050 |
Why?
|
| Phenylalanine | 1 | 2003 | 365 | 0.050 |
Why?
|
| Amino Acid Motifs | 2 | 2016 | 929 | 0.050 |
Why?
|
| Europe | 2 | 2019 | 3441 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2003 | 478 | 0.050 |
Why?
|
| Neutrophils | 2 | 1991 | 3767 | 0.050 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 3726 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 1992 | 3707 | 0.050 |
Why?
|
| Cell Differentiation | 5 | 2011 | 11481 | 0.050 |
Why?
|
| Cell Communication | 2 | 2000 | 1653 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2014 | 14372 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2019 | 2648 | 0.050 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 1007 | 0.050 |
Why?
|
| Organ Specificity | 2 | 1997 | 1955 | 0.050 |
Why?
|
| Dimerization | 1 | 2003 | 891 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2003 | 371 | 0.050 |
Why?
|
| Disease Progression | 5 | 2019 | 13502 | 0.050 |
Why?
|
| Staurosporine | 1 | 2002 | 242 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 20509 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 2234 | 0.050 |
Why?
|
| Herpesvirus 8, Human | 2 | 2013 | 255 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 6544 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 565 | 0.050 |
Why?
|
| Point Mutation | 1 | 2006 | 1594 | 0.050 |
Why?
|
| Alkaloids | 1 | 2002 | 194 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2007 | 7850 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2023 | 629 | 0.050 |
Why?
|
| Cell Survival | 4 | 2016 | 5797 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2010 | 1588 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 1993 | 4407 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 4024 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2004 | 1456 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2011 | 2725 | 0.040 |
Why?
|
| Alleles | 2 | 2012 | 6898 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2009 | 2566 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 1664 | 0.040 |
Why?
|
| Fibroblasts | 3 | 2004 | 4090 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2002 | 451 | 0.040 |
Why?
|
| Nocodazole | 1 | 1999 | 95 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 3084 | 0.040 |
Why?
|
| South America | 1 | 2019 | 181 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2006 | 1513 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2015 | 3426 | 0.040 |
Why?
|
| Response Elements | 1 | 2000 | 308 | 0.040 |
Why?
|
| Diagnostic Imaging | 2 | 2024 | 3527 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2000 | 421 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2006 | 2208 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2014 | 4642 | 0.040 |
Why?
|
| Biopsy | 2 | 2014 | 6771 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2000 | 454 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2002 | 859 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2003 | 559 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 1998 | 97 | 0.040 |
Why?
|
| Immunity | 1 | 2004 | 998 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 1246 | 0.040 |
Why?
|
| Melanoma | 1 | 2017 | 5697 | 0.040 |
Why?
|
| Tissue Array Analysis | 2 | 2012 | 551 | 0.040 |
Why?
|
| Molecular Weight | 2 | 1995 | 2186 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2007 | 2981 | 0.040 |
Why?
|
| G1 Phase | 1 | 1999 | 403 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2007 | 2299 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2022 | 788 | 0.040 |
Why?
|
| Survival Rate | 4 | 2016 | 12808 | 0.040 |
Why?
|
| alpha-Macroglobulins | 1 | 1998 | 60 | 0.040 |
Why?
|
| Chondroitin Sulfates | 1 | 1998 | 174 | 0.040 |
Why?
|
| Plasmids | 1 | 2003 | 2275 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2003 | 611 | 0.040 |
Why?
|
| Oral Health | 1 | 2003 | 486 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2016 | 1313 | 0.040 |
Why?
|
| Peptide Elongation Factor G | 1 | 2016 | 12 | 0.040 |
Why?
|
| Lymph Nodes | 3 | 2011 | 3486 | 0.040 |
Why?
|
| Alabama | 1 | 1997 | 104 | 0.040 |
Why?
|
| Myeloproliferative Disorders | 1 | 2003 | 609 | 0.040 |
Why?
|
| Peptide Elongation Factor Tu | 1 | 2016 | 18 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 3 | 2007 | 1705 | 0.040 |
Why?
|
| Phosphothreonine | 1 | 1996 | 62 | 0.040 |
Why?
|
| Macrophages | 3 | 2019 | 5745 | 0.030 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2016 | 38 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2009 | 1919 | 0.030 |
Why?
|
| Introns | 1 | 1999 | 978 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 1827 | 0.030 |
Why?
|
| Phosphoserine | 1 | 1996 | 203 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2000 | 2176 | 0.030 |
Why?
|
| World Health Organization | 1 | 2022 | 1312 | 0.030 |
Why?
|
| Asthma | 1 | 1995 | 6172 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 1996 | 122 | 0.030 |
Why?
|
| Risk Factors | 5 | 2019 | 74359 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1999 | 1167 | 0.030 |
Why?
|
| Gelatinases | 1 | 1996 | 88 | 0.030 |
Why?
|
| Catalysis | 1 | 1998 | 775 | 0.030 |
Why?
|
| Endothelial Growth Factors | 1 | 1998 | 673 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1997 | 286 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
| Kinetics | 3 | 1993 | 6377 | 0.030 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 1996 | 107 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1996 | 343 | 0.030 |
Why?
|
| Neoplasm Metastasis | 3 | 1998 | 4902 | 0.030 |
Why?
|
| Drug Stability | 1 | 1996 | 290 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2009 | 6216 | 0.030 |
Why?
|
| Lymphokines | 1 | 1998 | 927 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 2016 | 264 | 0.030 |
Why?
|
| Paraffin | 1 | 2014 | 37 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1999 | 1493 | 0.030 |
Why?
|
| Immune System | 2 | 1991 | 798 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2013 | 22053 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2007 | 749 | 0.030 |
Why?
|
| Cricetulus | 1 | 1996 | 815 | 0.030 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1995 | 169 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 1998 | 482 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2016 | 168 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 600 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 353 | 0.030 |
Why?
|
| Proteome | 2 | 2016 | 1855 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2016 | 363 | 0.030 |
Why?
|
| North America | 1 | 2018 | 1284 | 0.030 |
Why?
|
| Receptors, Mitogen | 1 | 2014 | 61 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1996 | 1433 | 0.030 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1994 | 180 | 0.030 |
Why?
|
| CHO Cells | 1 | 1996 | 1389 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2003 | 1710 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 1055 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 368 | 0.030 |
Why?
|
| Janus Kinases | 1 | 2014 | 250 | 0.030 |
Why?
|
| Chromatin | 1 | 2005 | 2938 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2016 | 548 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2003 | 635 | 0.030 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1993 | 92 | 0.030 |
Why?
|
| Amides | 1 | 1996 | 448 | 0.030 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 1992 | 37 | 0.030 |
Why?
|
| Androgens | 1 | 2000 | 1291 | 0.030 |
Why?
|
| Proteomics | 2 | 2024 | 3817 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 2471 | 0.030 |
Why?
|
| Benzeneacetamides | 1 | 1992 | 36 | 0.030 |
Why?
|
| Cricetinae | 1 | 1996 | 2427 | 0.030 |
Why?
|
| HEK293 Cells | 2 | 2012 | 4264 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 604 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 3113 | 0.030 |
Why?
|
| Genes, myc | 1 | 2013 | 395 | 0.030 |
Why?
|
| Receptors, Opioid | 1 | 1992 | 145 | 0.030 |
Why?
|
| 5'-Nucleotidase | 1 | 1993 | 161 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1997 | 1067 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1993 | 282 | 0.020 |
Why?
|
| Azepines | 1 | 2013 | 330 | 0.020 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1991 | 174 | 0.020 |
Why?
|
| Health Behavior | 1 | 2003 | 2622 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Citric Acid Cycle | 1 | 2012 | 230 | 0.020 |
Why?
|
| Cisplatin | 2 | 1996 | 1644 | 0.020 |
Why?
|
| L-Selectin | 1 | 1991 | 209 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1993 | 899 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 763 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 11345 | 0.020 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 174 | 0.020 |
Why?
|
| Glycosylation | 1 | 2014 | 1096 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 1991 | 286 | 0.020 |
Why?
|
| Mollusca | 1 | 1990 | 40 | 0.020 |
Why?
|
| Bronchi | 1 | 1994 | 848 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 979 | 0.020 |
Why?
|
| Infant | 3 | 2010 | 36060 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1992 | 1543 | 0.020 |
Why?
|
| RNA Splicing | 1 | 1995 | 915 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 1992 | 796 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 658 | 0.020 |
Why?
|
| Health Status | 1 | 2003 | 4081 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 566 | 0.020 |
Why?
|
| Pain | 1 | 2005 | 5066 | 0.020 |
Why?
|
| Age of Onset | 1 | 1997 | 3301 | 0.020 |
Why?
|
| Hypertension | 1 | 2009 | 8594 | 0.020 |
Why?
|
| Thioglycolates | 1 | 2009 | 38 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2013 | 80372 | 0.020 |
Why?
|
| DNA Primers | 1 | 1993 | 2819 | 0.020 |
Why?
|
| Epithelium | 1 | 1993 | 1605 | 0.020 |
Why?
|
| Calcium | 3 | 1992 | 5725 | 0.020 |
Why?
|
| Transforming Growth Factors | 1 | 1988 | 75 | 0.020 |
Why?
|
| Granulocytes | 1 | 1991 | 551 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 1992 | 1900 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1991 | 663 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 2138 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2023 | 9287 | 0.020 |
Why?
|
| Risk | 1 | 2000 | 9631 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1993 | 1529 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1999 | 3604 | 0.020 |
Why?
|
| Triazoles | 1 | 2013 | 904 | 0.020 |
Why?
|
| DNA Replication | 2 | 1993 | 1412 | 0.020 |
Why?
|
| Oncogenes | 1 | 1994 | 1220 | 0.020 |
Why?
|
| Peptides | 2 | 2007 | 4354 | 0.020 |
Why?
|
| Fetus | 2 | 1993 | 1859 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 15789 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1500 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2009 | 548 | 0.020 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2007 | 28 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 1991 | 1792 | 0.020 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2007 | 33 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2008 | 285 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 1987 | 79 | 0.020 |
Why?
|
| Visual Acuity | 1 | 1997 | 2643 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2011 | 453 | 0.020 |
Why?
|
| Age Factors | 3 | 2001 | 18416 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1988 | 310 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 8950 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2009 | 412 | 0.020 |
Why?
|
| Phenotype | 2 | 2016 | 16546 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1992 | 2381 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2012 | 22023 | 0.020 |
Why?
|
| Research | 1 | 2015 | 1974 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 2222 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1990 | 1249 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 1988 | 499 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 1990 | 521 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1990 | 975 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 877 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 1992 | 2414 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1987 | 586 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 361 | 0.020 |
Why?
|
| RNA Splice Sites | 1 | 2006 | 211 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2004 | 41 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 2006 | 281 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2012 | 1804 | 0.010 |
Why?
|
| Pneumonia | 1 | 2016 | 2131 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2004 | 102 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2004 | 185 | 0.010 |
Why?
|
| Tetracycline | 1 | 2004 | 220 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2006 | 388 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2009 | 1167 | 0.010 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 1447 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1984 | 2912 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3078 | 0.010 |
Why?
|
| HLA-D Antigens | 1 | 1983 | 134 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1983 | 346 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3616 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 675 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1983 | 337 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 626 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 12159 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1983 | 317 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1988 | 1387 | 0.010 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 1933 | 0.010 |
Why?
|
| Plasma Cells | 1 | 2006 | 591 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2009 | 3615 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 613 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1995 | 8555 | 0.010 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1984 | 264 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 482 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2004 | 731 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2003 | 271 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 483 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 678 | 0.010 |
Why?
|
| Carboplatin | 1 | 2005 | 788 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2003 | 385 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 474 | 0.010 |
Why?
|
| Laminin | 1 | 2003 | 405 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1983 | 630 | 0.010 |
Why?
|
| Models, Molecular | 1 | 1992 | 5434 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2012 | 3442 | 0.010 |
Why?
|
| Rural Health | 1 | 2003 | 296 | 0.010 |
Why?
|
| Unemployment | 1 | 2003 | 209 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 878 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1991 | 1915 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2014 | 3539 | 0.010 |
Why?
|
| Leukocytes | 1 | 2009 | 2026 | 0.010 |
Why?
|
| Urban Health | 1 | 2003 | 533 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1987 | 1889 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1989 | 4625 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2003 | 801 | 0.010 |
Why?
|
| Dental Care | 1 | 2003 | 279 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 1693 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 6180 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 1690 | 0.010 |
Why?
|
| Clone Cells | 1 | 2003 | 1660 | 0.010 |
Why?
|
| Monocytes | 1 | 2009 | 2575 | 0.010 |
Why?
|
| Child | 2 | 2024 | 79806 | 0.010 |
Why?
|
| Naloxone | 2 | 1992 | 369 | 0.010 |
Why?
|
| Tyrosine | 1 | 2003 | 1438 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2004 | 2057 | 0.010 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2000 | 296 | 0.010 |
Why?
|
| Case Management | 1 | 2001 | 272 | 0.010 |
Why?
|
| Thiophenes | 1 | 2003 | 587 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10344 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 1964 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1990 | 4357 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1988 | 2828 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2000 | 783 | 0.010 |
Why?
|
| DNA | 2 | 1993 | 7233 | 0.010 |
Why?
|
| Demography | 1 | 2003 | 1650 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2003 | 1077 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 7408 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24123 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2004 | 3094 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2003 | 968 | 0.010 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1988 | 1394 | 0.010 |
Why?
|
| Benzamides | 1 | 2003 | 1369 | 0.010 |
Why?
|
| Medically Uninsured | 1 | 2003 | 843 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2005 | 1736 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 2025 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 1835 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2003 | 1139 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 4035 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 18957 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 1529 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1986 | 6360 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2001 | 1247 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 21025 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2000 | 1130 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 7269 | 0.010 |
Why?
|
| United States | 2 | 2019 | 72461 | 0.010 |
Why?
|
| Collagen | 1 | 2003 | 2636 | 0.010 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 1 | 1992 | 9 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1993 | 374 | 0.010 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 1992 | 19 | 0.010 |
Why?
|
| 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 1992 | 20 | 0.010 |
Why?
|
| Thymidine | 1 | 1993 | 299 | 0.010 |
Why?
|
| Health Surveys | 1 | 2003 | 4063 | 0.010 |
Why?
|
| Enkephalins | 1 | 1992 | 139 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1997 | 54303 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1985 | 2299 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1993 | 406 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 14660 | 0.010 |
Why?
|
| Poverty | 1 | 2003 | 2695 | 0.010 |
Why?
|
| Choline | 1 | 1993 | 513 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 7806 | 0.010 |
Why?
|
| Metaphase | 1 | 1989 | 144 | 0.000 |
Why?
|
| Hybrid Cells | 1 | 1989 | 422 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1985 | 4319 | 0.000 |
Why?
|
| Logistic Models | 1 | 2003 | 13314 | 0.000 |
Why?
|
| Blotting, Southern | 1 | 1989 | 777 | 0.000 |
Why?
|
| Chromosome Banding | 1 | 1988 | 260 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1996 | 3618 | 0.000 |
Why?
|
| Receptors, Transferrin | 1 | 1989 | 291 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 1304 | 0.000 |
Why?
|
| Radiotherapy Dosage | 1 | 1993 | 2897 | 0.000 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 2693 | 0.000 |
Why?
|
| Analgesics | 1 | 1992 | 1065 | 0.000 |
Why?
|
| Oligopeptides | 1 | 1991 | 1187 | 0.000 |
Why?
|
| Brain Neoplasms | 1 | 1984 | 8986 | 0.000 |
Why?
|
| Protein Biosynthesis | 1 | 1989 | 2105 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1988 | 2608 | 0.000 |
Why?
|
| Radiography | 1 | 1991 | 6965 | 0.000 |
Why?
|
| Fluorouracil | 1 | 1985 | 1631 | 0.000 |
Why?
|
| Rats | 1 | 1989 | 23711 | 0.000 |
Why?
|
| Pregnancy | 1 | 1993 | 29749 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1985 | 42063 | 0.000 |
Why?
|